Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Prostatic Neoplasms 3Neoplasms 2Breast Neoplasms 2Tongue Neoplasms 1Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Endometrial Stromal 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Melanoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Fibrosarcoma 1Esophageal Neoplasms 1Dermatofibrosarcoma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Bone Neoplasms 1Bone Diseases 1

Interventions

Imatinib Mesylate 4Gemcitabine 2Doxorubicin 2Docetaxel 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2saracatinib 1pembrolizumab 1pazopanib 1envafolimab 1TTI-621 1Sunitinib 1Razoxane 1Radiotherapy, Intensity-Modulated 1Radiation Dose Hypofractionation 1Quality of Life 1Polymerase Chain Reaction 1Neoadjuvant Therapy 1MLN 8237 1Ipilimumab 1Gene Expression Profiling 1Dexrazoxane 1Dactinomycin 1Blotting, Western 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Dermatofibrosarcoma × saracatinib × Clear all
NCT00659360 2018-06-29

AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
17 enrolled 9 charts
GynecologicSarcoma

Fibrosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Endometrial Stromal, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡